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Abstract
Background: Direct-acting antivirals (DAAs) for chronic hepatitis C (CHC) treatment are tolerable and highly
effective in a shorter period of time than before. However, resistance-associated variants (RAVs) can affect the
efficacy of DAAs. The aim of this study was to investigate the real-life prevalence of RAVs against non-structural
protein 5A (NS5A) inhibitors in Korean patients with genotype 1b chronic hepatitis C.
Methods: All consecutive patients with CHC genotype 1b who underwent a RAV test at a single referral hospital
were enrolled.
Results: A total of 142 patients (male 53, female 89) were tested for RAVs. The average age of the patients was
58 years. Liver cirrhosis was found in 34.5% (49/142) of patients, and 19.0% (29/142) of patients had previously
undergone interferon-based treatment. Twenty-nine patients (20.4%) had RAVs (Y93 or L31). Y93H, L31, or Y93H
with L31 were detected in 22 (15.5%), 8 (5.6%), and 1 (0.7%) patients, respectively. The presence of RAV was not
affected by previous interferon-based treatment or by the existence of liver cirrhosis. Among 113 patients without
baseline NS5A RAVs, 72 patients started daclatasvir (DCV) + asunaprevir (ASV) treatment and 95% (68/72) patients
achieved virologic response at week 4. Virologic response at end of treatment and sustained virologic response at
12 weeks after treatment were achieved by 94% (68/72) and 94% (68/72), respectively.
Conclusions: In Korean patients with genotype 1b CHC, 20.4% (29 of 142) of patients showed RAVs against NS5A
inhibitors. Patient without RAVs who received treatment with DCV + ASV showed high virologic response rates in Korea.
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Background
Chronic hepatitis C virus (HCV) infection is one of the
main causes of liver cirrhosis and hepatocellular carcinoma
and is a principal cause of liver-related morbidity and mor-
tality worldwide. Previously, the standard treatment for pa-
tients with chronic hepatitis C (CHC) included pegylated-
interferon alpha (PEG-IFNα) and ribavirin therapy. [1]
Treatment response was not only related to HCV genotype
and the host’s interleukin (IL) 28B polymorphism but also
related to the tolerability of the drugs. Although Korean pa-
tients have favorable single nucleotide polymorphisms near
the IL28B gene, such as rs12979860CC and rs8099917TT
allele, [2] poor tolerability has led to the hesitation to use
interferon (IFN)-based treatment.
Recently, direct-acting antivirals (DAAs)—have been
developed and substituted IFN-based regimen to treat
patients with CHC. These DAAs are substantially more
tolerable and effective than PEG-IFNα and ribavirin. [3–
6] DAAs are molecules that target specific nonstructural
(NS) proteins of the virus and results in disruption of
viral replication and infection. There are four classes of
DAAs, which are defined by their mechanism of action
and therapeutic target. The four classes are NS proteins
3/4A protease inhibitors, NS5B nucleoside polymerase
inhibitors, NS5B non-nucleoside polymerase inhibitors,
and NS5A inhibitors. [7] Among the DAAs, combin-
ation treatment with daclatasvir (DCV) of NS5A inhibi-
tor and asunaprevir (ASV) of NS3 protease inhibitor
was introduced using multiple classes of DAAs with
non-overlapping targets. These regimens showed a good
treatment outcome in clinical trials of patients with
CHC genotype 1b, regardless of IFN-intolerance or lack
of response to IFN-based regimens. [8–10] Based on its
efficacy and safety compared to that of IFN-based ther-
apy, DCV + ASV combination therapy was the first IFN-
free regimen reimbursed by national health insurance in
Korea for the treatment of genotype 1b CHC.
However, a NS5A inhibitor, such as daclatasvir, has
limited efficacy with baseline resistance-associated vari-
ants (RAVs) at NS5A-Y93H and NS5A-L3l. DCV + ASV
combination therapy also showed various results de-
pending on the presence of RAVs. According to a previ-
ous study, in patients with a sustained virologic response
at 24 weeks post-treatment, the virus was eliminated in
98.6% of patients without NS5A polymorphism and in
42.1% of patients with NS5A polymorphism. [11] Thus,
regarding the efficacy of DCV + ASV therapy, the pres-
ence of RAVs, especially the presence of NS5A RAVs,
can be an important factor. However, impact of RAVs is
regimen specific, since reports have shown that SVR
rates after DCV combined with a different DAA was not
influenced from NS5A RAVs. [12, 13]
NS5A RAVs prevalence varied from 18% (population-
based sequencing) [6] to 29% (deep sequencing) in Japanese
patients. [14] As the prevalence of HCV genotypes is quite
different depending on the region, NS5A RAVs can vary
depending on the region or the country in which it is
treated, and the results and effects of DCV + ASV therapy
are assumed to vary accordingly. Thus, when using DAAs,
including NS5A inhibitors, investigating the real-life preva-
lence of NS5A RAVs in a specific area and its influence is
important. The aim of this study was to investigate the
real-life prevalence of RAVs against NS5A inhibitors in
Korean patients with genotype 1b CHC and the efficiency
of the treatment with DCV + ASV in patients with geno-
type 1b CHC without RAVs.
Methods
Patients
All consecutive patients with CHC who took the NS5A
RAVs test from August 2015 to May 2016 were enrolled.
Medical records were retrospectively reviewed, and data
were collected from a single referral hospital, in Seoul,
Korea. Patients were at least 20 years of age, with con-
firmed CHC genotype 1b infection and HCV RNA levels
≥10,000 IU/ml. Liver cirrhosis (LC) was diagnosed clin-
ically by morphologic changes of cirrhosis on imaging
studies or other signs of portal hypertension, such as
portosystemic shunt or hypersplenism. This study was
approved by the ethics committee of our hospital, and
the need for informed consent was waived.
Laboratory tests
HCV RNA was quantified using the Roche COBAS Taq-
Man assay (Roche Molecular Diagnostics, Pleasanton,
CA, USA) with a lower limit of quantification of 15 IU/
mL. HCV genotype and subtype were assessed using
HCV genotyping kit (Biosewoom Inc., Seoul, Korea).
The sequencing of a 408 bp fragment in the core gene
and 293 bp fragment in the 5′ untranslated region
(UTR) were used to assign genotypes. Genotypes of the
strains were analyzed using the HCV sequence database
(https://hcv.lanl.gov).
Direct sequencing of HCV NS5A Y93 and L31 gene re-
gions from plasma samples was performed. Viral RNA
was isolated from 200 μL plasma samples utilizing the
QIA Amp MiniElute Virus Vacuum Kit (Catalog No.
57714 Qiagen, Inc. Valencia, CA) and the QiaCube work-
station. Viral RNA was eluted in 25 uL of elution buffer
and 20 uL of eluate was used in the cDNA preparation.
The extracted RNA was reverse transcribed and amplified
by the PCR method using the SuperScript III One-Step
RT-PCR System with Platinum Taq DNA Polymerase
(Invitrogen) with the pairs of primers as follows: sense
(5872–5891) 5′-AAGAGGCTCCACCAGTGGAT-3′ and
antisense (6730–6749) 5′-CGCCGGAGCGTACCTGT
GCA-3′. The PCR products were purified using a QIA-
quick PCR Purification Kit (QIAGEN) and sequenced
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using an automated DNA sequencer (3730xl DNA
Analyzer, Applied Biosystems). Two primer sets for se-
quencing through the NS5A L31 and Y93 coding regions
are: forward sequencing primer (1bseqF2) 5′-TCCG
GCTCGTGGCTAAGAGATGTTTGGG-3′ and reverse
sequencing primer (1bseqR5) 5′-CAGTGGTCATGCCC
GTCACGTAGTG-3′. Each sequence was confirmed for
the sense and antisense strands. If minor sequences of
RAV were detected in more than 10% of the strength of
the major sequence, it was regarded as RAV positive. [15]
Treatment
HCV treatment was based on guidelines of the Korean As-
sociation for the Study of the Liver (KASL). [16] According
to the guidelines presented in 2015, patients with NS5A
RAVs were recommended to be treated with ledipasvir/
sofosbuvir. If patients without NS5A RAVs agreed to CHC
treatment with firstly approved DAAs, DCV + ASV, they
received DCV (one 60 mg tablet once daily) and ASV (one
100 mg capsule twice daily) combination therapy for
24 weeks as guidelines recommended. Patients were
followed-up during treatment and for more than 12 weeks.
Virologic response was defined as undetectable HCV RNA
level at each time point. Virologic responses on week 4 of
treatment, at the end of treatment, and 12 weeks post-
treatment were checked. Before starting these therapies, the
presence of current liver cirrhosis or a past patient’s history
of IFN-based treatment was not considered for exclusion.
However, patients who were currently being treated for
HCC or refused to be treated were excluded from receiving
DCV + ASV therapy.
Statistical analysis
Continuous variables were presented as mean ± SD or
median (interquartile range). Categorical variables were
compared between groups by the chi-squared test. The
Student’s t-test was used to compare the mean of continu-
ous variables. A value of p < 0.05 was considered statisti-
cally significant. All statistical tests were performed with
PASW version 17.0 (IBM Corp., Armonk, NY, USA).
Results
Baseline characteristics of patients
A total of 142 patients (male 53, female 89) were tested
for RAVs at NS5A-Y93 and NS5A-L31. The average age of
the patients was 58 years old (range: 24–90). LC was
found in 34.5% (49/142) of patients, and 19.0% (27/142) of
patients had previously undergone IFN-based treatment.
Among the patients who underwent IFN-based treatment,
22 failed the treatment and 5 discontinued the treatment
because of adverse hematologic events. Among the pa-
tients without NS5A RAVs, 72 patients underwent
DCV + ASV therapy for 24 weeks. A comparison of the
characteristics of patients in the RAV-positive and RAV-
negative groups is shown in Table 1. RAV-positive patients
were significantly older than RAV-negative patients. Other
factors were not different between the groups.
Real-life prevalence of NS5A RAV
Of the 142 patients, 22 patients (15.5%) had a Y93H
RAV, and 8 patients (5.6%) had an L31 RAV in the
NS5A RAV test. When considering L31 RAV, L31 M
was the most common, being present in four patients,
followed by L31I, present in two patients, and L31F and
L31 V, which were present in one patient each. More-
over, one case had both Y93H and L31 V RAVs. Hence,
29 of the 142 patients (20.4%) had at least one NS5A
RAV (Fig. 1). When comparing the RAV-positive pa-
tients who had undergone IFN-based treatment with
treatment-naïve patients, 24% (6/25) of the patients who
had undergone IFN-based treatment had RAVs, and 20%
(23/117) of the treatment-naïve patients had RAVs. Fur-
thermore, 27% (13/49) of patients who had cirrhosis had
RAVs, while only 17% of the patients (16/93) without
cirrhosis had RAVs (Fig. 2).
Efficacy of DCV + ASV combination therapy
A total of 72 of 113 RAV-negative patients started
DCV + ASV therapy. Two patients stopped DCV + ASV
medication because of adverse events within four weeks
of starting the treatment. Other 2 patients who had low
detectable levels of HCV RNA at week 4 continued the
medication, and finally achieved virologic response at
week 24 and SVR12. Among the 68 patients who
achieved virologic response at week 4, only 1 patient did
not achieve virologic response at week 24. Furthermore, 1
patient who achieved virologic response at week 4 stopped
medication because of liver enzyme elevation at week 7
Table 1 Baseline characteristics and laboratory findings of
patients who underwent RAV test
Total
(n = 142)
RAV negative
(n = 113)
RAV positive
(n = 29)
P value
Male, n (%) 53 (37.3%) 43 (38%) 10 (35%) 0.723
Age, years 58 ± 14 55 ± 14 66 ± 11 < 0.001
LC, n (%) 49 (34.5%) 36 (32%) 13 (45%) 0.190
Treatment
experienced,
n (%)
25 (17.6%) 19 (17%) 6 (21%) 0.624
AST, IU/L 58.4 ± 36.5 59.1 ± 38.9 56.0 ± 25.9 0.685
ALT, IU/L 51.5 ± 52.0 52.9 ± 55.5 46.0 ± 35.3 0.526
Total bilirubin,
mg/dL
0.91 ± 0.52 0.92 ± 0.5 0.87 ± 0.34 0.601
HCV RNA, ×
106 IU/mL
2.241 ± 2.996 2.046 ± 3.024 3.013 ± 2.799 0.127
All results are presented as n (%) or mean ± SD
LC liver cirrhosis, AST aspartate aminotransferase, ALT alanine
aminotransferase, RAV resistance-associated variant
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without virologic rebound during the therapy (Fig. 3). This
patient experienced virologic rebound only after stopping
medication. In summary, 94% (68/72) patients achieved
virologic response at week 4. Virologic response at week
24 and SVR12 were achieved by 94% (68/72) and 94% (68/
72) of patients, respectively (Fig. 4a).
Treatment-naïve patients showed virologic response
rates at week 4, week 24 and SVR12 as 97%, 95% and 95%,
respectively. Patients who had received IFN-based treat-
ment previously showed virologic response rates at week
4, week 24 and SVR12 as 86%, 93% and 93%, respectively.
However, no significant differences were shown by experi-
ence of IFN-based treatment (Fig. 4b).
Comparing the responses depending on the presence
of cirrhosis, 95% (55/58) of patients who did not have
accompanying cirrhosis achieved SVR12, and 93% (13/
14) of patients who had cirrhosis achieved SVR12. There
was little difference between the patients with and
without accompanying cirrhosis in terms of achieving
virologic response at week 4 and 24 (Fig. 4c).
Characteristics of patients who discontinued DAA
treatment
After the start of DCV + ASV treatment, 3 patients fi-
nally discontinued treatment because of adverse events
(Table 2). One patient who had underlying idiopathic
thrombocytopenic purpura (ITP) was confirmed to have
AST/ALT elevation at 7th week of treatment. In this
case, the patient had no choice but to stop the therapy
because her AST/ALT levels increased to greater than
10 times of normal limit. In the second case, the patient
was diagnosed with petechia, which occurred in the
whole body, from the second week of the treatment. Be-
cause the patient had a history of cured ITP 20 years
ago, an initial impression of recurred ITP was suspected
in the emergency room blood test.Since no causes other
Fig. 1 Real-life prevalence of NS5A resistance-associated variants (RAVs) in patients with chronic hepatitis C genotype Ib
Fig. 2 Comparison of non-structural protein 5A resistance-associated variants (RAVs) prevalence based on previous interferon-based treatment
experience (a) and liver cirrhosis (LC) (b) in patients with chronic hepatitis C genotype 1b
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Fig. 3 Flow chart of the participants and the outline of study. Among resistance-associated variants (RAVs) negative patients, 72 patients who
agreed to start daclatasvir plus asunaprevir (DCV + ASV) therapy were analyzed for treatment response. Virologic response was determined if a
level of serum HCV RNA is less than lower limit of quantification (LLOQ)
Fig. 4 Efficacy of daclatasvir plus asunaprevir combination therapy for chronic hepatitis C genotype 1b: virologic response in total patients (a),
comparison of virologic response based on liver cirrhosis (LC, b) and previous treatment experience (c)
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than the newly administered DCV + ASV were found,
the patient stopped taking DCV + ASV therapy, and the
platelet count recovered after a steroid treatment. The
patient is now under follow-up care after hospital dis-
charge. In the last case, the patient wanted to stop treat-
ment because of severe general weakness and fatigue at
the second week of treatment. All these patient had viral
rebound viral after halting treatment.
Discussion
Development of new drugs for HCV infection, one of the
world’s major health crises, provides an opportunity to
come one step closer to its complete cure. In particular, it
provides an opportunity for complete cures for patients
who have failed IFN and ribavirin treatment, thus allowing
easier treatment because of fewer adverse effects. DAAs
mainly act on nonstructural proteins that are formed by the
HCV. RAVs are known to drastically reduce the efficiency
of these drugs [6, 17, 18]. Therefore, when prescribing these
drugs, such as DCV + ASV, the presence of RAVs needs to
be confirmed before starting the treatment and setting the
treatment direction. If RAVs vary depending on the regions
and countries in which patients live, DAAs’ performance
can be expected to differ accordingly. In the previous era of
IFN-based treatment, IL28B genetic polymorphisms
showed differences between Asian and non-Asian coun-
tries, and that treatment performance varied accordingly.
[19–22] About 90% of the population of Korea are CC ho-
mozygotes, [2, 23, 24] and response of IFN-based treatment
was relatively higher than in Western people. Because
IL28B test is not routinely performed before treatment of
CHC as guidelines suggested, [16] IL28B was not evaluated
in these patients. Therefore, we could not figure out
whether the presence of baseline RAVs differed significantly
with respect to IL28B genotype.
Currently availabilities of DAAs differ from country to
country. DCV + ASV began to be used in Japan after its
approval in 2014, and it has been used in Korea since Au-
gust 2015 after its insurance application was approved.
Therefore, because of its limited use thus far, insufficient
investigation has been made into the treatment perform-
ance of DCV + ASV and its related NS5A mutations. In
this study, the real-life prevalence of NS5A RAVs detected
at baseline in 142 Korean patients was investigated and
Table 2 Patients’ characteristics who discontinued daclatasvir plus asunaprevir treatment
Reference
levels
Patients who discontinued treatment because of adverse events
Patient 1 Patient 2 Patient 3
Cause of discontinuation AST/ALT elevation Thrombocytopenia General weakness
Fatigue
Toxicity grade by CTCAE Grade 3 Grade 4 Grade 3
Age/Sex 45/F 49/F 79/F
HCV RNA, IU/ml 194,000 1,390,000 5,620,000
Liver cirrhosis No No Yes
Comorbidities ITP HTN HTN, DM
Baseline
White blood cells, ×109/L 4.0–10.8 6150 6800 7290
Hemoglobin, g/dL 12–15.9 12.6 13.9 16.5
Platelets,×109/L 150–400 23 158 144
AST/ALT, IU/L 13–36/1–46 21/27 49/54 88/97
Total bilirubin, mg/dL 0.2–1.3 0.5 0.7 0.9
Albumin, mg/dL 3.4–5.3 3.6 4.1 3.9
Prothrombin time, INR 0.96–1.16 1.21 1.04 1.17
At week 4
White blood cells, ×109/L 4.0–10.8 6410 7990 10,770
Hemoglobin, g/dL 12–15.9 14.0 13.4 17
Platelets, ×109/L 150–400 19 < 5 160
AST/ALT, IU/L 13–36/1–46 265/450 29/15 86/101
Total bilirubin, mg/dL 0.2–1.3 1.0 0.6 1.0
Albumin, mg/dL 3.4–5.3 4.1 4.3 4.4
Prothrombin time, INR 0.96–1.16 1.41 0.99 1.13
CTCAE common terminology criteria for adverse events, ITP idiopathic thrombocytopenic purpura, DM diabetes mellitus, HTN hypertension, AST aspartate
aminotransferase, ALT alanine aminotransferase, INR international normalized ratio
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was confirmed to be slightly higher prevalence than was
previously reported. [25–27] According to data published
in Japan in 2015, the incidence of NS5A mutations in
Japan was 18.4%, which was higher than its incidence in
non-Asian countries. [6] Although further studies are
needed in the future, in regards to patients with CHC
genotype 1b in Asia, frequent NS5A RAVs detected at
baseline are considered a substantial limitation in
DCV + ASV use, and other DAA regimens need to be
considered because impact of RAVs is regimen specific.
[12, 13]
According to our results, the RAV-positive incidence
was not different in patients who was naïve or who failed
prior IFN-based treatment. Furthermore, in patients
with accompanying cirrhosis, the RAV-positive incidence
was not statistically different. It is assumed that these
patients have been infected with viruses for a long time
and have retained viruses with diverse mutations, but
again, the exact causes are not known. However, good
treatment performance was observed in RAV-negative
patients in this study, regardless of presence of cirrhosis
or whether prior IFN-based treatments had failed. Pa-
tients who reached virologic response during treatment
also reached SVR12 without much difficulty.
The number of patients with NS5A RAVs is slightly
higher than the previously reported data of 12–18.4%.
[25–27] Although further studies are needed in the future,
according to our study results, the number of HCV geno-
type 1b–infected Korean patients without NS5A RAVs,
and therefore suitable for treatment with DCV + ASV,
might be slightly less than that in other regions or coun-
tries where the prevalence of these NS5A RAVs are less.
DAA-based treatment has relatively fewer adverse effects
than IFN-based treatment. However, in the case with DCV,
patients can have headaches, general weakness, and fatigue.
Bradycardia arrhythmias have been observed in patients re-
ceiving amiodarone with DCV and sofosbuvir, with or with-
out other drugs that lower heart rate. The mechanism for
the bradycardia effect has not been clearly established; re-
cent in vivo studies have demonstrated a sofobuvir amioda-
rone drug-drug interaction (DDI)-dependent selective
nodal dysfunction resulting in bradycardia. [28] Moreover,
ASV can have adverse effects including diarrhea, headache,
hyperbilirubinemia, and increased transaminase level. Add-
itionally, cases that were assumed to be immunoallergic
hepatitis after DCV + ASV combination therapy have been
reported. [29] According to a large scaled report of
DCV + ASV therapy, 2.9% of patients discontinued the
therapy as a result of ALT elevation. ALT elevation more
than 1.25-fold the upper limit of normal was noted in
37.6% of patients. [30] Another large scaled study revealed
that discontinuation due to liver injury occurred in 28 of
924 patients (3.0%). Other minor cause of discontinuation
was fatigue, diarrhea, nausea, appetite loss, pneumonia,
rash, platelet decrease and encephalopathy. [31] In a multi-
center study among hemodialysis patients, 4 of 123 patients
discontinued DCV + ASV therapy because of elevated
serum alanine transaminase levels (n = 2), rash (n = 1), and
HCC; all of these achieved SVR12. [32] In this study, three
patients stopped treatment because of adverse effects, one
of which was marked thrombocytopenia. One patient’s
platelet count dropped from normal to very low 2 weeks
after beginning treatment. This patient stopped the treat-
ment, and the platelet levels returned to normal after ster-
oid treatment. However, since the medicine can be
accompanied by additional complications that can be life-
threatening, hematologic disorders need to be carefully
monitored during the treatment, though this patient has a
history of cured ITP. Another patient had to stop treatment
because of weakness and fatigue. Fatigue is often observed
as an adverse effect of DCV + ASV therapy, and typically, it
is not severe enough to stop treatment. However, the drug
can result in general weakness and fatigue too severe for
this patients to endure. The other patient discontinued
DCV + ASV therapy due to elevated transaminases at week
7 after achieving virologic response at week 4. In this study,
since adverse effects occurred within 2 month of the treat-
ment in all cases, more careful observation is needed in the
early period of treatment.
Limitations of the study are the limited sample size
and dataset from a single center study. Although hepa-
titis B is endemic in Korea, Hepatitis C is not as preva-
lent as in Japan or in western countries. Thus, sample
size is relatively small comparing other reports form
these regions. These clinical data are collected in one
tertiary referral hospital. Therefore, patients nationwide
are included even though these results can not accur-
ately reflect the patient across the country.
Conclusions
In patients with HCV infection, when RAV is not present,
DCV + ASV therapy has shown good treatment perform-
ance regardless of the presence of cirrhosis or previous
IFN-based treatment experience. Therefore, DCV + ASV
therapy can be expected to be actively used to treat CHC
genotype 1b without NS5A RAVs. However, since there
are a considerable number of RAV-positive cases, other
DAA regimens need to be considered. The possibility of
complications resulting from the treatment, although rare,
needs to be considered and monitored with regular
hepatic function tests.
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